Click Therapeutics
Click Therapeutics is redefining modern medicine with patient-centric digital treatments, developing, validating, and commercializing software as prescription medical treatments.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Click Therapeutics is a company that develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. It operates at the intersection of biology and technology, combining neuroscience with the power of software to create a new way to treat disease. The company was founded by David Benshoof Klein, who recognized the impact of smartphones on behavior and cognition and created the term 'Digital Therapeutics™'.
History
Click Therapeutics was founded by David Benshoof Klein, who in 2012 recognized the enormous impact of smartphones on behavior and cognition. He created the term 'Digital Therapeutics™' and founded Click Therapeutics to develop, validate, and commercialize software as prescription medical treatments. The company develops software both for standalone use as Prescription Digital Therapeutics (PDTs) and combination use as Software-Enhanced Drugs™ (SE Drugs).
Products and positioning
Click Therapeutics positions itself as a company where science meets software, developing software as treatment that is delivered to the phone and prescribed by a physician. It emphasizes a platform-based approach that combines scientifically proven therapies with proprietary neuromodulatory mechanisms of action.
CT-152 Rejoyn
Indicated for Major Depressive Disorder (MDD), in launch phase.
AspyreRx
Indicated for Type 2 Diabetes, FDA Authorized.
CT-132
Indicated for Episodic Migraine, FDA Authorized.
CT-155
Indicated for Schizophrenia, Phase 3: Pivotal/Reg.
CT-156
Indicated for Schizophrenia, Phase 2: Dev/Pilot.
CT-102
Indicated for Opioid Use Disorder (OUD), Phase 2: Dev/Pilot.
CT-133
Indicated for Multiple Sclerosis (MS), Phase 1: Discovery.
CT-171
Indicated for Atopic Dermatitis, Phase 1: Discovery.
CT-181
Indicated for Obesity, Phase 1: Discovery.
CT-191
Indicated for Oncology, Phase 1: Discovery.
CT-141
Indicated for Insomnia, Phase 1: Discovery.
CT-111
Indicated for Acute Coronary Syndrome, Phase 1: Discovery.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/click-therapeutics · Editorial policy · How profiles are compiled